LRIG inhibitors of growth factor signalling - double-edged swords in human cancer?
The leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins are newly discovered negative regulators of growth factor signalling and proposed tumour suppressors. They antagonise signalling by interacting with growth factor receptors and by enhancing their ubiquitylation and degradation. Data on the expression of LRIG in human cancer have recently begun to accumulate; however, not all data appear consistent with the notion that the LRIG proteins always function as tumour suppressors. In the present review, we argue that the LRIG proteins could be double-edged swords, promoting or suppressing human cancer depending on cellular context.
Hedman
Håkan
H
Department of Radiation Sciences, Oncology, Umeå University, SE-90187 Umeå, Sweden. hakan.hedman@onkologi.umu.se
Henriksson
Roger
R
D002450:Cell Communication; D049109:Cell Proliferation; D005544:Forecasting; D006706:Homeostasis; D006801:Humans; D008562:Membrane Glycoproteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D009369:Neoplasms / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D013234:Stem Cells / Q000502:physiology
D008562:Membrane Glycoproteins; D011505:Protein-Tyrosine Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; C484445:LRIG1 protein, human